"A pioneer is always a creator"

Shlomo Assa, co-founder and President, Acclaro Corporation, is a world leader in laser technology with 30+ years of experience in the medical aesthetic industry and a deep understanding of tissue interaction physics. Founded in 2019 by world-class industry experts and top physicians in the nation, Acclaro Corporation is a US-based, fast-growing medical device company committed to innovating and developing game-changing solutions to address today’s most challenging unmet needs in the global medical aesthetic, ophthalmic, and surgical markets.

Shlomo spotted the opportunities with the Mid-IR Fiber laser from the very beginning, developing the implementation technology that ultimately became part of the UltraClear System. The Acclaro team invented proprietary technologies that use the fiber laser properties to optimize clinical efficacy and safety while significantly reducing patient pain sensation.

Acclaro Corporation, led by Shlomo Assa, had a clear vision from the very beginning, trusting that the team's success would come once the product becomes real and was ready for commercialization. With such a deep conviction and belief in the company's direction, the founders dedicated their utmost to creating the product prototype by working tirelessly 14–18 hours a day, 7 days a week for over 2.5 years to reduce the company’s expenses and deliver the results that the company needed.

The valuable lesson that Shlomo learnt from his career is that the most important asset that companies have is their human capital. Many entrepreneurs are mistaken by thinking that funding is the most important resource they need, but for Shlomo, the most important resource is the people, and that is where the company's management focuses.

Acclaro’s innovation is focused on better efficacy with increased safety while improving dramatically both patient and provider experience. Acclaro’ s technology reduces pain level and treatment duration, so the overall patient experience becomes very positive, and at the same time, significantly increases provider productivity and income. Also, Acclaro offers productivity subscription tools that improve provider capabilities, in contrast to other companies that force consumable costs to enrich their corporate instead of increasing the provider income. We believe in bringing disruptive technology that creates a new category of treatments, says Acclaro management.

Acclaro’s flagship product, UltraClear™, is the world's first and only cold, ablative fiber laser platform, a breakthrough painless anti-aging solution and the first ablative laser that does not require topical numbing for most sessions. UltraClear™ is a high-speed, all-skin-type, all-in-one platform with unrivalled energy control capabilities to achieve a wide range of skin rejuvenation results from genuine, painless, and zero-downtime anti-aging lunchtime treatments to the most advanced collagen remodeling with superior outcomes. It has a 15-minute average full-face treatment time and the highest level of patient safety and comfort.

UltraClear™, offers a revolutionary lunchtime anti-aging treatment. 3DMIRACL™  which is a no-downtime treatment that stimulates natural exfoliation and gently peels away the topmost layer of dull and damaged skin, revealing silky, soft, and smooth skin with a daily glow. 3DMIRACL™ is a 10-minute professional treatment that produces predictable and outstanding results. It is the first medical laser therapy to offer a rapid and comfortable solution for patients wanting regular skin regimens, as well as recurring income streams for providers without the need for consumables, resulting in a faster return on investment. 3DMIRACL™ saves at least one hour of prep time for both patients and providers by eliminating the need for topical numbing substance. This is the only anti-aging laser treatment in the market that does not require numbing cream.

 

Taking an idea from conception to commercialization in less than 2.5 years, including FDA clearance and the formation of a commercial team, is a world-class accomplishment. Large organizations, on the other hand, will need to invest far more money and take 5–10 years to attain the same benefits. The Acclaro team is concentrating on a number of upcoming indications that will expand UltraClear’s potential. Following clinical trials, the FDA will approve further indications, which will address a few important unmet needs among patients and providers.

Acclaro Corporation was able to secure round A financing before receiving FDA clearance and before having clinical results, which indicates the level of trust that the team achieved with both KOL’s and investors. The Acclaro mission will always be there to offer worldwide physicians and their patients innovative energy-based medical solutions with the best-in-class quality, performance, efficacy, and safety that improve quality of life.